Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flexion's Zilretta Poised For Market Of Diabetics With Knee Pain

Executive Summary

FDA labeling in knee pain osteoarthritis is favorable for long-acting steroid Zilretta and a sales force is lined up, but Flexion has its commercial work cut out competing with very cheap generics.

Advertisement

Related Content

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016
Keeping Track: Flexion's Non-Opioid Knee Pain Drug Gets OK, Botox Gets Another Approval
Flexion CEO Makes The Case For Zilretta
Flexion's OA Knee Injection On Track For H2 Filing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel